Literature DB >> 21606645

Dendrin location in podocytes is associated with disease progression in animal and human glomerulopathy.

Katsuhiko Asanuma1, Miyuki Akiba-Takagi, Fumiko Kodama, Rin Asao, Yoshiko Nagai, Aida Lydia, Hiromitsu Fukuda, Eriko Tanaka, Terumi Shibata, Hisatsugu Takahara, Teruo Hidaka, Etsuko Asanuma, Eiki Kominami, Takashi Ueno, Yasuhiko Tomino.   

Abstract

BACKGROUND: Adriamycin (ADR) nephrosis in mice has been extensively studied and has enabled a greater understanding of the processes underlying the progression of renal injury. Dendrin is a novel component of the slit diaphragm with proapoptotic signaling properties, and it accumulates in the podocyte nucleus in response to glomerular injury in mice. The present study re-evaluated chronic progressive nephropathy in ADR mice and the localization of dendrin in mice and in human glomerulopathy.
METHODS: To investigate the localization of dendrin, a mouse model of nephrosis and glomerulosclerosis was used, in which ADR was injected once. WT-1-positive cells and apoptotic cells were counted in vivo and in vitro. To check the expression of dendrin in ADR mice, immunostaining and Western blot were performed. A survey of dendrin staining was performed on human kidney biopsy specimens.
RESULTS: The injection of ADR induced proteinuria, podocyte loss and glomerulosclerosis. It also caused the relocation of dendrin from the slit diaphragm to the podocyte nucleus. We demonstrated the location of dendrin to podocyte nuclei in several cases of human glomerulopathy. The mean occurrence of dendrin-positive nucleus per glomerulus increased in several cases of human glomerulopathy.
CONCLUSIONS: These findings suggest that the relocation of dendrin to the podocyte nuclei is useful as a novel marker of podocyte injury in human glomerulopathy.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21606645     DOI: 10.1159/000327995

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  23 in total

1.  Re-expression of Sall1 in podocytes protects against adriamycin-induced nephrosis.

Authors:  Yoshiko Hosoe-Nagai; Teruo Hidaka; Ayano Sonoda; Yu Sasaki; Kanae Yamamoto-Nonaka; Takuto Seki; Rin Asao; Eriko Tanaka; Juan Alejandro Oliva Trejo; Fumiko Kodama; Miyuki Takagi; Nobuhiro Tada; Takashi Ueno; Ryuichi Nishinakamura; Yasuhiko Tomino; Katsuhiko Asanuma
Journal:  Lab Invest       Date:  2017-07-31       Impact factor: 5.662

2.  Glomerulosclerosis Induced by Deficiency of Membrane-Associated Guanylate Kinase Inverted 2 in Kidney Podocytes.

Authors:  Naritoshi Shirata; Kan-Ichiro Ihara; Kanae Yamamoto-Nonaka; Takuto Seki; Shin-Ichi Makino; Juan Alejandro Oliva Trejo; Takafumi Miyake; Hiroyuki Yamada; Kirk Nicholas Campbell; Takahiko Nakagawa; Kiyoshi Mori; Motoko Yanagita; Peter Mundel; Katsuhiko Nishimori; Katsuhiko Asanuma
Journal:  J Am Soc Nephrol       Date:  2017-05-24       Impact factor: 10.121

3.  Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy.

Authors:  Rin Asao; Katsuhiko Asanuma; Fumiko Kodama; Miyuki Akiba-Takagi; Yoshiko Nagai-Hosoe; Takuto Seki; Yukihiko Takeda; Isao Ohsawa; Satoshi Mano; Kiyoshi Matsuoka; Hiroyuki Kurosawa; Shinya Ogasawara; Yoshiaki Hirayama; Sakari Sekine; Satoshi Horikoshi; Masanori Hara; Yasuhiko Tomino
Journal:  Clin J Am Soc Nephrol       Date:  2012-06-14       Impact factor: 8.237

4.  CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival.

Authors:  Suma Yaddanapudi; Mehmet M Altintas; Andreas D Kistler; Isabel Fernandez; Clemens C Möller; Changli Wei; Vasil Peev; Jan B Flesche; Anna-Lena Forst; Jing Li; Jaakko Patrakka; Zhijie Xiao; Florian Grahammer; Mario Schiffer; Tobias Lohmüller; Thomas Reinheckel; Changkyu Gu; Tobias B Huber; Wenjun Ju; Markus Bitzer; Maria P Rastaldi; Phillip Ruiz; Karl Tryggvason; Andrey S Shaw; Christian Faul; Sanja Sever; Jochen Reiser
Journal:  J Clin Invest       Date:  2011-09-12       Impact factor: 14.808

5.  Dendrin ablation prolongs life span by delaying kidney failure.

Authors:  Astrid Weins; Jenny S Wong; John M Basgen; Ritu Gupta; Ilse Daehn; Lisette Casagrande; David Lessman; Monica Schwartzman; Kristin Meliambro; Jaakko Patrakka; Andrey Shaw; Karl Tryggvason; John Cijiang He; Susanne B Nicholas; Peter Mundel; Kirk N Campbell
Journal:  Am J Pathol       Date:  2015-06-12       Impact factor: 4.307

6.  Intrinsic disorder and amino acid specificity modulate binding of the WW2 domain in kidney and brain protein (KIBRA) to synaptopodin.

Authors:  Ethiene Kwok; Diego J Rodriguez; Joachim Kremerskothen; Afua Nyarko
Journal:  J Biol Chem       Date:  2019-10-09       Impact factor: 5.157

7.  Synaptopodin Is Dispensable for Normal Podocyte Homeostasis but Is Protective in the Context of Acute Podocyte Injury.

Authors:  Liang Ning; Hani Y Suleiman; Jeffrey H Miner
Journal:  J Am Soc Nephrol       Date:  2020-09-16       Impact factor: 10.121

8.  Yes-associated protein (YAP) promotes cell survival by inhibiting proapoptotic dendrin signaling.

Authors:  Kirk N Campbell; Jenny S Wong; Ritu Gupta; Katsuhiko Asanuma; Marius Sudol; John Cijiang He; Peter Mundel
Journal:  J Biol Chem       Date:  2013-05-10       Impact factor: 5.157

9.  Cathepsin D in Podocytes Is Important in the Pathogenesis of Proteinuria and CKD.

Authors:  Kanae Yamamoto-Nonaka; Masato Koike; Katsuhiko Asanuma; Miyuki Takagi; Juan Alejandro Oliva Trejo; Takuto Seki; Teruo Hidaka; Koichiro Ichimura; Tatsuo Sakai; Norihiro Tada; Takashi Ueno; Yasuo Uchiyama; Yasuhiko Tomino
Journal:  J Am Soc Nephrol       Date:  2016-01-28       Impact factor: 10.121

10.  Podocyte-Specific Deletion of Yes-Associated Protein Causes FSGS and Progressive Renal Failure.

Authors:  Monica Schwartzman; Antoine Reginensi; Jenny S Wong; John M Basgen; Kristin Meliambro; Susanne B Nicholas; Vivette D'Agati; Helen McNeill; Kirk N Campbell
Journal:  J Am Soc Nephrol       Date:  2015-05-26       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.